Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer
Authors
Keywords
CRPC, Docetaxel, Risk model, ALP, Hemoglobin, Age
Journal
International Journal of Clinical Oncology
Volume 19, Issue 5, Pages 946-954
Publisher
Springer Nature
Online
2013-11-22
DOI
10.1007/s10147-013-0638-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
- (2013) Pirkko-Liisa Kellokumpu-Lehtinen et al. LANCET ONCOLOGY
- Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy
- (2012) Gregory R. Pond et al. BJU INTERNATIONAL
- Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan
- (2012) Kazuo Nishimura et al. International Journal of Clinical Oncology
- Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel
- (2012) Takashi Kawahara et al. PLoS One
- Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
- (2011) Gregory R. Pond et al. EUROPEAN UROLOGY
- Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study
- (2011) Tomoyuki Shimabukuro et al. International Journal of Clinical Oncology
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer
- (2011) Hideaki Miyake et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Prognostic Impact of C-reactive Protein for Determining Overall Survival of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel
- (2011) Masaya Ito et al. UROLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
- (2009) Andrew J. Armstrong et al. EUROPEAN JOURNAL OF CANCER
- Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy
- (2009) Kenji Kuroda et al. PROSTATE
- C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer
- (2008) Tomasz M. Beer et al. CANCER
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search